Midgard Science

WuXi STA

Changzhou, China sta.wuxiapptec.com

From their website, Nov 2026

Work here? Claim this listing

About

WuXi STA provides contract development and manufacturing services for small-molecule and synthetic-molecule pharmaceuticals. It serves clients globally from facilities across Asia, North America, and Europe, supporting projects from preclinical through commercial stages.

Services

  • API process development

    Develops synthetic routes and process R&D for starting materials, intermediates, and active pharmaceutical ingredients from preclinical to commercial launch.

  • API manufacturing

    Manufactures small-molecule intermediates, building blocks, and drug substance from gram to metric-ton scale.

  • High potency API

    Provides process R&D and manufacturing for high-potency APIs, including facilities handling HP compounds with an OEL of 10 ng/m3.

  • Flow chemistry

    Offers process development, non-GMP, and GMP production services using continuous manufacturing flow chemistry.

  • Biocatalysis

    Uses enzyme-based biocatalysis for stereoselective biotransformations and enantiomer resolutions.

  • Drug product oral solid development

    Supports pre-formulation, formulation development, and manufacturing for oral solid dosage forms.

  • Pre-formulation

    Studies physicochemical properties to support selection of developable molecules at the preclinical stage.

  • Formulation development

    Develops oral solid formulations from preclinical to commercial manufacturing.

  • Oral solid state development

    Characterizes solid-state properties of APIs and drug products for oral solid dosage development.

  • Drug product parenteral development

    Provides pre-formulation, formulation, and analytical support for parenteral projects from preclinical studies through commercial launch.

  • Parenteral manufacturing

    Manufactures injectable drug products at scale for various dosage forms and filling formats.

  • Clinical supply service

    Provides clinical trial materials from Phase I to Phase IV through an integrated CMC platform.

  • Analytical development and quality control

    Provides analytical method development, validation, testing, quality control, and stability studies for drug substance and drug product programs.

  • Regulatory CMC dossier preparation

    Prepares CMC dossiers to support global regulatory filings.

  • Spray dried dispersion

    Provides spray-dried dispersion capabilities from laboratory to production scale.

  • Process Development

    Provides API process development for synthetic drugs from preclinical to clinical and commercial launch, including starting materials, intermediates, and API.

  • Manufacturing

    Manufactures starting material, intermediate, and drug substance within a global supply chain network.

    CDMO: development & manufacturing

  • Preparative HPLC, SFC, and SMB

    Uses preparative HPLC, supercritical fluid chromatography, and simulated moving bed chromatography as enabling technologies.

  • Crystallization and Particle Engineering

    Provides crystallization and particle engineering support within the drug substance platform.

  • Drug Product Development

    Provides formulation development and manufacturing from preclinical to commercial phase.

  • Parenteral Development

    Supports parenteral dosage form development and manufacturing.

  • Lipid Nanoparticle Platform

    Provides lipid nanoparticle capabilities from laboratory to production scale.

  • Hot Melt Extrusion

    Offers hot melt extrusion as a bioavailability-enhancing technology.

  • Lipid Formulation

    Provides lipid formulation development support.

  • Nano Suspension

    Provides nanosuspension development support.

  • Reference Standard Characterization and Qualification

    Provides reference standard characterization and qualification as part of analytical services.

  • Regulatory Dossier Preparation

    Prepares CMC submission packages and regulatory dossiers for IND, IMPD, and NDA submissions.

Lead time
6-8 weeks to prepare IND submission package for US FDA
What to send
Work Email · Company / Institution · Country / Region · First Name · Last Name · Job Title

Capabilities

As they state on their website or in their listing.

Processes
Small molecule · Peptide · Oligonucleotide · LNP / formulation · LNP · Process development · Small molecules · HPLC · Peptides · Oligonucleotides · Analytical development · Stability studies
Capacity
Few grams to metric ton scale · OEL of 10 ng/m3 · 5 production lines · Total reactor volume exceeds 4,000 m3 · 6 sites in Asia and North America · 3,600+ process chemists and analytical scientists · 1,500+ formulators & analytical scientists · 3,500+ analytical scientists · OEL ≥10 ng/m³ · 2024: 1,000+ preclinical-phase III molecules supported · 50+ late-phase NCEs validated · 10+ commercial products supported
1 more740+ CMC submission packages written during 2019-2024
Scales
Gram · Kilogram · Ton
Data supplied
HPLC

Equipment

  • Prep-HPLC
  • SFC
  • SMB
  • Spray dryers

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

Company

Type
CRDMO
Team
3,600+ process chemists and analytical scientists; 1,500+ formulators & analytical scientists; 3,500+ analytical scientists

Locations

Address
Manufacturing 20+ years' experience Over 20 years of experience in API manuf
Sites
Shanghai Waigaoqiao, China · Shanghai, China · Wuxi City, China · Taixing, China · Changzhou, China · Jinshan, China · Tuas, Singapore · Middletown, Delaware, USA · San Diego, California, USA · Couvet, Neuchâtel, Switzerland · Shanghai Jinshan, China
Serves
globally, Asia, North America, Europe, 105 countries, worldwide

Similar labs

Work here? Claim this listing